Sorafenib vs. half dose Sorafenib and UFT combined therapy in patients with Hepatocellular carcinoma refractory to TACE: Randomised Prospective Study.

Trial Profile

Sorafenib vs. half dose Sorafenib and UFT combined therapy in patients with Hepatocellular carcinoma refractory to TACE: Randomised Prospective Study.

Recruiting
Phase of Trial: Phase II

Latest Information Update: 13 Feb 2014

At a glance

  • Drugs Sorafenib (Primary) ; Tegafur/uracil (Primary)
  • Indications Liver cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 13 Feb 2014 Status changed from not yet recruiting to recruiting as reported by University Hospital Medical Information Network - Japan record.
    • 18 Dec 2013 Additional lead trial centre/investigator identified as reported by University Hospital Medical Information Network - Japan record.
    • 11 Dec 2013 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top